Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells $656,259.90 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 13,099 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at approximately $628,554.60. This trade represents a 51.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 2.8%

Shares of NASDAQ:KNSA opened at $55.27 on Friday. The firm’s 50 day moving average price is $46.40 and its 200 day moving average price is $43.12. The stock has a market cap of $4.23 billion, a price-to-earnings ratio of 61.41 and a beta of 0.17. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $24.85 and a fifty-two week high of $55.28.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.11 earnings per share. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.22 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup raised their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday. Wedbush raised their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research note on Wednesday. Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Friday, April 17th. Finally, Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and a consensus price target of $60.86.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Rubric Capital Management LP increased its position in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after purchasing an additional 90,194 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after purchasing an additional 49,802 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after purchasing an additional 332,846 shares in the last quarter. Qube Research & Technologies Ltd increased its position in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55% YoY); management raised FY‑2026 revenue guidance, improving near‑term revenue visibility. Q1 Results & Guidance
• Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises
• Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL‑387 Phase‑2 readout (recurrent pericarditis) is expected 2H‑2026 with a planned Phase‑3 start by year‑end, offering future catalysts. Product & Pipeline
• Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation
• Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre‑arranged 10b5‑1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short‑term negative sentiment despite being pre‑planned. CEO SEC Filing
• Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.